Amisulpride (Solian)

A benzamide derivative that is used as an antipsychotic agent for the treatment of schizophrenia. It is also used as an antidepressive agent.

Also Known As:

Solian; 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide; Barnetil; DAN 2163; DAN-2163; LIN 1418; LIN-1418; N-(Ethyl-1-pyrrolidinyl- 2-methyl)methoxy-2-ethylsulfonyl-5-benzamide; Sultopride; Sultopride Hydrochloride

Networked: 651 relevant articles (114 outcomes, 207 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133

Experts

1.	Leucht, Stefan: 32 articles (01/2022 - 02/2002)
2.	Komossa, Katja: 15 articles (01/2014 - 04/2009)
3.	Kissling, Werner: 15 articles (01/2012 - 02/2002)
4.	Rummel-Kluge, Christine: 14 articles (01/2014 - 04/2009)
5.	Fleischhacker, W Wolfgang: 13 articles (11/2020 - 12/2003)
6.	Hunger, Heike: 13 articles (02/2013 - 04/2009)
7.	Schwarz, Sandra: 13 articles (02/2013 - 04/2009)
8.	Kahn, René S: 12 articles (01/2021 - 10/2005)
9.	Schmid, Franziska: 10 articles (01/2012 - 10/2009)
10.	Reeves, Suzanne: 8 articles (12/2019 - 10/2014)

Related Diseases

1.	Schizophrenia (Dementia Praecox) 01/01/2021 - "Our data suggest that an early self-report cognitive function in amisulpride-treated schizophrenia is important in predicting for symptomatic remission, the fewer scores of PDQ20 at baseline mean the patients have less daily cognitive difficulty, the more likely the patient is to achieve symptomatic remission." 04/01/2010 - "This demonstrated significant improvement in subjective well-being in patients with schizophrenia initiating treatment with amisulpride, and a correlation between this improvement and amelioration of psychopathology. " 01/01/2002 - "Amisulpride is clinically effective on the negative symptoms of acute schizophrenia exacerbations at low dosages (50-300 mg/day), and also on the positive symptoms of the disease at high dosages (400-800 mg/day). " 09/01/1986 - "These results also suggest that sultopride would have good therapeutic efficacy in schizophrenic disorders." 01/01/2010 - "Amisulpride is effective in acute schizophrenia as determined by Clinical Global Impression scores. "
2.	Psychotic Disorders (Schizoaffective Disorder) 11/01/2018 - "The study investigated whether or not low-dose amisulpride is superior to placebo in reducing psychosis symptoms over 12 weeks and if any benefit is maintained by continuing treatment thereafter. " 01/01/2018 - "We investigated whether low-dose amisulpride (100 mg daily) is superior to placebo in reducing psychosis symptoms over 12 weeks and whether any benefit is maintained by continuing treatment after 12 weeks. " 01/01/2015 - "This means that there are two main advantages that ensue from the use of amisulpride: a patient's psychosis is more likely to go into remission and patients are less likely to stop taking the drug. " 07/01/2017 - "These findings argue strongly for the consideration of age- and weight-based dose adjustments in older patients with AD-related psychosis and indicate that 50 mg/d of amisulpride may be both the minimal clinically effective dose and, in those aged > 75 years, the maximally tolerated dose." 03/01/2007 - "In conclusion, amisulpride is an appropriate first-line treatment for the management of acute psychosis."
3.	Dysthymic Disorder 12/01/2002 - "The body of studies supports the view that amisulpride is an effective and well-tolerated treatment for dysthymia and dysthymia with major depression." 06/01/2019 - "Amisulpride (AMS) in low dosage has been used effectively for treatment of dysthymia. " 12/08/2010 - " studies (1313 participants) presented data on amisulpride treatment for dysthymia. " 12/01/2002 - "Amisulpride has now been investigated extensively in placebo controlled and in comparator controlled studies in patients suffering from dysthymia, both pure dysthymia and dysthymia with major depression. " 01/01/1999 - "Results of the present study in a large patient population further confirm the safe use of amisulpride in dysthymia and support its administration upon a medium-term treatment period."
4.	Postoperative Nausea and Vomiting (PONV) 10/01/2021 - "In 2 trials on the treatment of PONV, a significantly greater percentage of patients who received amisulpride 10 mg compared with placebo experienced a complete response (31.4% vs 21.5%, respectively, in patients who had not received prophylaxis; 41.7% vs 28.5%, respectively, in patients who had received prophylaxis). " 01/01/2021 - "Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting." 01/01/2017 - "The D2 /D3 antagonist amisulpride has shown promising efficacy against postoperative nausea and vomiting (PONV) at low doses. " 07/01/2020 - "Efficacy of amisulpride on postoperative nausea and vomiting: a systematic review and meta-analysis." 04/01/2020 - " covered: In this review, the authors discuss the pharmacological profile as well as clinical safety and efficacy of intravenous amisulpride and its relevance in the management of PONV. "
5.	Weight Gain 01/01/2008 - "Observational drug-utilization studies suggest that many physicians switch to amisulpride because of fewer EPS and/or less weight gain and improved patient adherence. " 01/01/2020 - "Weight gain was defined as the increase in body mass index from before until approximately 1 month after amisulpride treatment. " 06/01/2015 - "The mean weight gain with amisulpride at 4 weeks was 2.73 kg (5.21%) and at 8 weeks was 4.34 kg (8.28%) from the baseline. " 05/01/2006 - "Acute weight gain induced by amisulpride monotherapy in a first-episode schizophrenic patient." 04/01/2004 - "To analyse the weight gain associated with amisulpride. "

Related Drugs and Biologics

1.	Antipsychotic Agents (Antipsychotics)
2.	Olanzapine (Zyprexa)
3.	Risperidone (Risperdal Consta)
4.	Clozapine (Clozaril)
5.	Haloperidol (Haldol)
6.	Quetiapine Fumarate (Seroquel)
7.	ziprasidone (Geodon)
8.	Antidepressive Agents (Antidepressants)
9.	Dopamine (Intropin)
10.	Fluoxetine (Prozac)

Related Therapies and Procedures

1.	Therapeutics
2.	General Anesthesia
3.	Drug Therapy (Chemotherapy)
4.	Polypharmacy
5.	Length of Stay